Richard Tullis - Aethlon Medical Insider

Aethlon Medical Inc -- USA Stock  

USD 0.99  0.0011  0.11%

Chief Science Officer and VP

Dr. Richard H. Tullis Ph.D. is Chief Science Officer of the Company. He was Vice President Director of Aethlon Medical Inc. Dr. Tullis has extensive biotechnology management and research experience and is the founder of Syngen Research formerly a wholly owned subsidiary of Aethlon Medical Inc. Previously Dr. Tullis cofounded Molecular Biosystems Inc. a former NYSE company. At Molecular Biosystems Dr. Tullis was Director of Oligonucleotide Hybridization Senior Research Scientist and Member of the Board of Directors. In research Dr. Tullis developed and patented the first application of oligonucleotides to antisense antibiotics and developed new methods for the chemical synthesis of DNA via methoxyhosphorochloridites. Dr. Tullis also codeveloped the first applications of covalently coupled DNAenzyme conjugates using synthetic oligonucleotides during his tenure at Molecular Biosystems. In 1985 Dr. Tullis founded and served as President and CEO of Synthetic Genetics Inc. a pioneer in custom DNA synthesis which was sold to Molecular Biology Resources in 1991. Dr. Tullis also served as interimCEO of Genetic Vectors Inc. which completed its IPO under his management and was cofounder of DNA Sciences Inc. a company that was eventually acquired by Genetic Vectors
Age: 69  VP Since 2015  Ph.D    
858-459-7800  http://www.aethlonmedical.com
Tullis received his Ph.D. in Biochemistry and Cell Biology from the University of California at San Diego, and has done extensive postdoctoral work at UCSD, USC, and the University of Hawaii.

Management Efficiency

The company has return on total asset (ROA) of (388.73) % which means that it has lost $388.73 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (696.62) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 1.05 M in liabilities with Debt to Equity (D/E) ratio of 87.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aethlon Medical Inc has Current Ratio of 0.88 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Found 2 records

VP Since

Rob StefanicSensata Technologies Holding N
N/A
Rodney GonsalvesAgilent Technologies Inc
2015

Entity Summary

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in cancer, infectious diseases, and other lifethreatening conditions in the United States. Aethlon Medical Inc (AEMD) is traded on Nasdaq Capital Markets in USA. It is located in CALIFORNIA, U.S.A and employs 5 people. Aethlon Medical is listed under Measuring and Control Equipment category by Fama And French industry classification.

Did you try this?

Run Piotroski F Score Now
   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Hide  View All  Next  Launch Piotroski F Score
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Aethlon Medical Inc to your portfolio

Top Management

Aethlon Medical Inc Leadership Team
John Marco, Executive
James Joyce, Chairman
Franklyn Barry, Director
Rodney Kenley, Director
Edward Broenniman, Director
RAC PharMD, Executive
James Frakes, CFO, MBA
Richard Tullis, VP, Ph.D
Chetan Shah, Director, Ph.D

Stock Performance

Aethlon Medical Performance Indicators